Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

[1]  E. Winer,et al.  Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Moja,et al.  Trastuzumab-containing regimens for metastatic breast cancer. , 2014, The Cochrane database of systematic reviews.

[3]  F. Jänicke,et al.  Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry , 2014, BMC Cancer.

[4]  D. Amadori,et al.  Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. , 2013, The oncologist.

[5]  A. Santoro,et al.  Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  H. Rugo,et al.  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.

[7]  A. Musolino,et al.  Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer , 2011, Cancer.

[8]  J. Syrios,et al.  Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report , 2010, Journal of medical case reports.

[9]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Monfardini,et al.  When Should Trastuzumab be Stopped after Achieving Complete Response in Her2-Positive Metastatic Breast Cancer Patients? , 2007, Tumori.

[11]  K. Hess,et al.  Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[13]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.